{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:05:54Z","timestamp":1791338754131,"version":"4.3.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In <jats:italic>TP53<\/jats:italic> wild-type acute myeloid leukemia (AML), inhibition of MDM2 can enhance p53 protein expression and potentiate leukemic cell apoptosis. MDM2 inhibitor (MDM2i) monotherapy in AML has shown modest responses in clinical trials but combining options of MDM2i with other potent AML-directed agents like cytarabine and venetoclax could improve its efficacy. We conducted a phase I clinical trial (NCT03634228) to study the safety and efficacy of milademetan (an MDM2i) with low-dose cytarabine (LDAC)\u00b1venetoclax in adult patients with relapsed refractory (R\/R) or newly diagnosed (ND; unfit) <jats:italic>TP53<\/jats:italic> wild-type AML and performed comprehensive CyTOF analyses to interrogate multiple signaling pathways, the p53-MDM2 axis and the interplay between pro\/anti-apoptotic molecules to identify factors that determine response and resistance to therapy. Sixteen patients (14\u2009R\/R, 2\u2009N\/D treated secondary AML) at a median age of 70 years (range, 23\u201380 years) were treated in this trial. Two patients (13%) achieved an overall response (complete remission with incomplete hematological recovery). Median cycles on trial were 1 (range 1\u20137) and at a median follow-up of 11 months, no patients remained on active therapy. Gastrointestinal toxicity was significant and dose-limiting (50% of patients\u2009\u2265\u2009grade 3). Single-cell proteomic analysis of the leukemia compartment revealed therapy-induced proteomic alterations and potential mechanisms of adaptive response to the MDM2i combination. The response was associated with immune cell abundance and induced the proteomic profiles of leukemia cells to disrupt survival pathways and significantly reduced MCL1 and YTHDF2 to potentiate leukemic cell death. The combination of milademetan, LDAC\u00b1venetoclax led to only modest responses with recognizable gastrointestinal toxicity. Treatment-induced reduction of MCL1 and YTHDF2 in an immune-rich milieu correlate with treatment response.<\/jats:p>","DOI":"10.1038\/s41408-023-00871-1","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T05:01:49Z","timestamp":1688014909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis"],"prefix":"10.1038","volume":"13","author":[{"given":"Jayastu","family":"Senapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muharrem","family":"Muftuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-3562","authenticated-orcid":false,"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4895","authenticated-orcid":false,"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel I.","family":"Dara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Basyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Pourebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-9548","authenticated-orcid":false,"given":"Steven M.","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-1958","authenticated-orcid":false,"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"871_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/leu.2016.350","volume":"31","author":"A Quint\u00e1s-Cardama","year":"2017","unstructured":"Quint\u00e1s-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, et al. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia 2017;31:1296\u2013305.","journal-title":"Leukemia"},{"key":"871_CR2","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1038\/sj.onc.1203015","volume":"18","author":"ND Lakin","year":"1999","unstructured":"Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644\u201355.","journal-title":"Oncogene"},{"key":"871_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/cdd.2010.35","volume":"17","author":"L Collavin","year":"2010","unstructured":"Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010;17:901\u201311.","journal-title":"Cell Death Differ"},{"key":"871_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","volume":"69","author":"J Momand","year":"1992","unstructured":"Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237\u201345.","journal-title":"Cell"},{"key":"871_CR5","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1073\/pnas.0507493103","volume":"103","author":"C Tovar","year":"2006","unstructured":"Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci. 2006;103:1888\u201393.","journal-title":"Proc Natl Acad Sci"},{"key":"871_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","volume":"22","author":"M Andreeff","year":"2016","unstructured":"Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, et al. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res. 2016;22:868\u201376.","journal-title":"Clin Cancer Res"},{"key":"871_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","volume":"32","author":"R Pan","year":"2017","unstructured":"Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, et al. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017;32:748\u201360.e6","journal-title":"Cancer Cell"},{"key":"871_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1182\/blood-2019-123711","volume":"134","author":"NG Daver","year":"2019","unstructured":"Daver NG, Garcia JS, Jonas BA, Kelly KR, Assouline S, Brandwein JM, et al. Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R\/R) AML Ineligible for Cytotoxic Chemotherapy. Blood 2019;134:229.","journal-title":"Blood"},{"key":"871_CR9","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.2022016362","volume":"141","author":"NG Daver","year":"2023","unstructured":"Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, et al. Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial. Blood 2023;141:1265\u201376.","journal-title":"Blood"},{"key":"871_CR10","doi-asserted-by":"publisher","first-page":"P203","DOI":"10.1158\/1535-7163.TARG-21-P203","volume":"20","author":"V Ananthapadmanabhan","year":"2021","unstructured":"Ananthapadmanabhan V, Knott A, Soroko KM, Gokhale PC, Tirunagaru V, Doebele R, et al. Abstract P203: Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines. Mol Cancer Therapeutics. 2021;20:P203\u2013P.","journal-title":"Mol Cancer Therapeutics"},{"key":"871_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1182\/blood.V128.22.593.593","volume":"128","author":"CD DiNardo","year":"2016","unstructured":"DiNardo CD, Rosenthal J, Andreeff M, Zernovak O, Kumar P, Gajee R, et al. Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results. Blood. 2016;128:593.","journal-title":"Blood"},{"key":"871_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424\u201347.","journal-title":"Blood"},{"key":"871_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood.2021013983","volume":"140","author":"M Tashakori","year":"2022","unstructured":"Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood 2022;140:58\u201372.","journal-title":"Blood"},{"key":"871_CR14","first-page":"4147","volume":"6","author":"MY Konopleva","year":"2022","unstructured":"Konopleva MY, R\u00f6llig C, Cavenagh J, Deeren D, Girshova L, Krauter J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022;6:4147\u201356.","journal-title":"Blood Adv"},{"key":"871_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.2022016362","volume":"141","author":"NG Daver","year":"2022","unstructured":"Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, et al. Venetoclax and idasanutlin in relapsed\/refractory AML: a non-randomized, open-label phase 1b trial. Blood. 2022;141:1265\u201376.","journal-title":"Blood"},{"key":"871_CR16","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1073\/pnas.1620262114","volume":"114","author":"EA Chapeau","year":"2017","unstructured":"Chapeau EA, Gembarska A, Durand EY, Mandon E, Estadieu C, Romanet V, et al. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf\u2212\/\u2212 mouse model. Proc Natl Acad Sci USA. 2017;114:3151\u20136.","journal-title":"Proc Natl Acad Sci USA."},{"key":"871_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12555-1","volume":"10","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Goyama S, Liu X, Tamura M, Asada S, Tanaka Y, et al. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nat Commun. 2019;10:4869.","journal-title":"Nat Commun."},{"key":"871_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood 2021;138:234\u201345.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00871-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00871-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00871-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T05:02:14Z","timestamp":1688014934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00871-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00871-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EJ: reports research grants from Abbvie, Adaptive Biotechnologies, Amgen, Pfizer, and Takeda; and consultancy fees from Abbvie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Genentech, Incyte, Novartis, Pfizer, and Takeda. NJS reports research grants from Takeda Oncology, Astellas Pharma, Xencor, and Stemline Therapeutics; consultancy fees from Pfizer and Jazz Pharmaceuticals; and honoraria from Novartis, Amgen, Sanofi, and BeiGene. NP reports research grants from Novartis, Stemline Therapeutics, Samus Therapeutics, Abbvie, Cellectics, Affymetrix\/Thermo Fisher Scientific, Daiichi Sankyo, Plexxikon, MustangBio, honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, Abbvie, MustangBio, Roche Molecular Diagnostics, Blueprint Medicines, DAVA Pharmaceuticals, Springer Science+Business Media LLC, Aptitude Health, NeoPharm, CareDX, Consulting or advisory role in Blueprint Medicines, Pacylex Pharmaceuticals Inc., Immunogen, Mristol Myers Squibb, Clearview Healthcare Partners, Astellas Pharma US Inc., Protagonist Therapeutics, Triptych Health Partners, CTI BioPharma Corp and Travel\/accommodation expenses from Stemline Therapeutics, Celgene, Abbvie, DAVA oncology, MustangBio. ND: reports research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen; and served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck labs, and Agios. HK: reports research grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi-Sankyo, Immunogen, Jazz, Novartis, and Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, Astra Zeneca, Ipsen, Pharmaceuticals, KAHR Medical, NOVA Research, Novartis, Pfizer, Precision Biosciences, and Taiho Pharmaceutical Canada. All other authors declare no competing interests. MA: reports research funding from AstraZeneca, Amgen, Daiichi Sankyo, Jazz, GlycoMimetics; consultancy fees from Amgen, AstraZeneca, Daiichi Sankyo, Syndax, GlycoMimetics, Oncoceutics, and Aptose; and holds stock from Reata, Oncoceutics\/Chimerix and Aptose. CDD: reports research grants from Abbvie, Agios\/Servier, Astex, Calithera, Celgene\/BMS, Cleave, Daiichi-Sankyo, ImmuneOnc, Loxo; honoraria\/consulting fees from Abbvie, Agios\/Servier, Astellas, Celgene\/BMS, Cleave, Foghorn, Genentech, Novartis, Notable Labs, Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was approved by the Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"101"}}